Financials in USD. Standardized financial statements.
A compact view of how Autolus Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $75.56M | $10.12M | $1.70M | $6.19M | $1.51M | $1.72M | $2.91M | $1.05M | $1.69M | $1.21M |
| Revenue Growth? | +646.7% | +496.0% | -72.6% | +311.0% | -12.1% | -41.0% | +178.2% | -38.3% | +39.7% | 0.0% |
| Cost of Revenue? | $96.59M | $141.02M | $0 | $0 | $0 | $134.89M | $105.42M | $48.30M | $1.01M | $478,000 |
| Gross Profit? | -$21.03M | -$130.90M | $1.70M | $6.19M | $1.51M | -$133.17M | -$102.51M | -$47.25M | $684,000 | $734,000 |
| Gross Margin? | -27.8% | -1293.5% | +100.0% | +100.0% | +100.0% | -7765.2% | -3525.1% | -4520.4% | +40.4% | +60.6% |
| Operating Expenses? | $260.41M | $110.53M | $181.40M | $149.09M | $141.88M | $169.96M | $145.07M | $41.48M | $25.11M | $15.59M |
| Operating Income? | -$281.44M | -$241.43M | -$179.70M | -$142.89M | -$140.37M | -$303.13M | -$247.58M | -$57.53M | -$23.42M | -$14.38M |
| EBITDA? | -$271.60M | -$233.07M | -$156.77M | -$132.24M | -$132.47M | -$162.58M | -$137.40M | -$50.32M | -$22.41M | -$13.90M |
| Income Before Tax | -$296.85M | -$219.13M | -$208.40M | -$148.57M | -$142.04M | -$166.26M | -$108.69M | -$36.33M | -$23.38M | -$14.33M |
| Income Tax Expense | -$8.65M | $1.53M | -$19,000 | $272,000 | $58,000 | -$24.16M | $15.16M | -$5.21M | -$3.65M | -$1.78M |
| Net Income? | -$288.20M | -$220.66M | -$208.38M | -$148.84M | -$142.10M | -$142.09M | -$123.85M | -$31.11M | -$19.73M | -$12.55M |
| EPS? | $-1.08 | $-0.87 | $-1.20 | $-1.57 | $-1.97 | $-2.76 | $-2.88 | $-0.99 | $-1.43 | $-0.91 |
| Diluted EPS? | $-1.08 | $-0.87 | $-1.20 | $-1.57 | $-1.97 | $-2.76 | $-2.88 | $-0.99 | $-1.43 | $-0.91 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality